De Greef, Axel http://orcid.org/0000-0003-0713-8283
Benjelloun, Ghita
Harkemanne, Evelyne http://orcid.org/0000-0001-9936-9868
Baeck, Marie http://orcid.org/0000-0003-0499-7939
Article History
Received: 17 January 2024
Accepted: 12 February 2024
First Online: 5 March 2024
Declarations
:
: Marie Baeck discloses her past participation on the upadacitinib advisory boards organized by AbbVie. Axel De Greef and Marie Baeck have previously participated as speakers in events sponsored by AbbVie. Ghita Benjelloun and Evelyne Harkemanne disclose no conflict of interest. All the authors declare that the current study was conducted in an independent manner.
: This case report and data collection were conducted with the approval of the hospital and faculty institutional review board (Commission d’Ethique Biomédicale Hospitalo-Facultaire) of Université catholique de Louvain (UCLouvain), Belgium. All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The patient in this manuscript has given written informed consent to participate and for publication of her case details.